Enveric Biosciences, Inc.
ENVB
Rank in Stocks
#29931
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse... Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Share Price
$1.44
Last synced: 2026-11-09
Market Cap
$6.45M
Change (1 day)
1.12%
Change (1 year)
-75.76%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Enveric Biosciences, Inc. (ENVB)
Category
Healthcare
EPS for Enveric Biosciences, Inc. (ENVB)
EPS as of June 2026 TTM: $-16.46
According to Enveric Biosciences, Inc.'s latest financial reports, its current EPS (TTM) is $-16.46. At the end of 2025 the company had an EPS of $-36.24, an increase over its 2024 EPS of $-228.48.
EPS history for Enveric Biosciences, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-16.46 | -54.58% |
| 2025 | $-36.24 | -84.14% |
| 2024 | $-228.48 | 135.35% |
| 2023 | $-97.08 | -37.77% |
| 2022 | $-156.00 | -87.46% |
| 2021 | $-1.24K | 86.83% |
| 2020 | $-666.00 | -73.82% |
| 2019 | $-2.54K | -94.03% |
| 2018 | $-42.62K | 17.25% |
| 2017 | $-36.35K | 184.63% |
| 2016 | $-12.77K | 24.95% |
| 2015 | $-10.22K | 343.01% |
| 2014 | $-2.31K | 16,192.37% |
| 2013 | $-14.16 | -99.34% |
| 2012 | $-2.16K | -26.24% |
| 2011 | $-2.92K | -54.90% |
| 2010 | $-6.48K | -32.63% |
| 2009 | $-9.62K | -59.24% |
| 2008 | $-23.61K | -117.79% |
| 2007 | $132.70K | -272.47% |
| 2006 | $-76.94K | 332.59% |
| 2005 | $-17.79K | -50.12% |
| 2004 | $-35.66K | -68.21% |
| 2003 | $-112.18K | -2,808.59% |
| 2002 | $4.14K | -107.62% |
| 2001 | $-54.36K | -162.85% |
| 2000 | $86.49K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -195.14% |
US
|
|
| $-7.07 | -57.05% |
US
|
|
| $-5.29 | -67.86% |
AU
|
|
| $12.88 | -178.25% |
BE
|
|
| $21.56 | -230.98% |
NL
|
Questions about Enveric Biosciences, Inc.'s earnings per share (EPS)
What is Enveric Biosciences, Inc.'s earnings per share (EPS)?
Enveric Biosciences, Inc.'s earnings per share (EPS) over the last twelve months is $-16.46, as of Jun 2026.
What was Enveric Biosciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Enveric Biosciences, Inc.'s earnings per share (EPS) was $-36.24, compared with $-228.48 in 2024.
How has Enveric Biosciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Enveric Biosciences, Inc.'s earnings per share (EPS) was highest in 2025 ($-36.24) and lowest in 2021 ($-1.24K).
How does Enveric Biosciences, Inc.'s earnings per share (EPS) compare with similar companies?
Enveric Biosciences, Inc.'s earnings per share (EPS) ($-16.46) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.